JP2020514349A - 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用 - Google Patents

癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用 Download PDF

Info

Publication number
JP2020514349A
JP2020514349A JP2019549542A JP2019549542A JP2020514349A JP 2020514349 A JP2020514349 A JP 2020514349A JP 2019549542 A JP2019549542 A JP 2019549542A JP 2019549542 A JP2019549542 A JP 2019549542A JP 2020514349 A JP2020514349 A JP 2020514349A
Authority
JP
Japan
Prior art keywords
ref
ape1
cancer
therapeutic agent
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019549542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514349A5 (https=
Inventor
マーク アール． ケリー
マーク アール． ケリー
メリッサ エル． フィッシェル
メリッサ エル． フィッシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of JP2020514349A publication Critical patent/JP2020514349A/ja
Publication of JP2020514349A5 publication Critical patent/JP2020514349A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019549542A 2017-03-20 2018-03-20 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用 Pending JP2020514349A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762473528P 2017-03-20 2017-03-20
US62/473,528 2017-03-20
US201762521082P 2017-06-16 2017-06-16
US62/521,082 2017-06-16
PCT/US2018/023346 WO2018175429A1 (en) 2017-03-20 2018-03-20 Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2020514349A true JP2020514349A (ja) 2020-05-21
JP2020514349A5 JP2020514349A5 (https=) 2021-03-18

Family

ID=63586117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549542A Pending JP2020514349A (ja) 2017-03-20 2018-03-20 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用

Country Status (5)

Country Link
US (3) US20190160034A1 (https=)
EP (2) EP3430057A4 (https=)
JP (1) JP2020514349A (https=)
CA (1) CA3056240A1 (https=)
WO (1) WO2018175429A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
EP3897601A4 (en) * 2018-12-17 2022-08-31 Indiana University Research And Technology Corporation TREATMENT OF GASTROINTESTINAL DISEASES AND THEIR SYMPTOMS
CA3121645A1 (en) * 2018-12-20 2020-06-25 Rafael Pharmaceuticals, Inc. Oral therapy using 6,8-bis-benzylthio-octanoic acid
CN111840228A (zh) * 2019-04-09 2020-10-30 中国科学院上海药物研究所 肿瘤免疫脂质体，其制备方法和用途
WO2021034635A1 (en) * 2019-08-16 2021-02-25 Rafael Pharmaceuticals, Inc. Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and a glutaminase inhibitor
GB201913124D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CN115317619B (zh) * 2021-05-10 2025-10-17 北京化工大学 一种核酸纳米载药体及其应用
EP4587003A2 (en) 2022-09-14 2025-07-23 Opus Genetics, Inc. Salts and esters of apx3330 and therapeutic uses thereof
WO2025147565A1 (en) * 2024-01-05 2025-07-10 Indiana University Research And Technology Corporation Treatment of necrotizing enterocolitis and symptoms thereof
WO2025231402A1 (en) * 2024-05-03 2025-11-06 Indiana University Research And Technology Corporation Methods of inhibiting retinal degeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540544A (ja) * 2007-09-26 2010-12-24 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 癌および血管新生の治療のための、化学療法剤と組み合わせたベンゾキノン誘導体ｅ３３３０
JP2014516051A (ja) * 2011-05-26 2014-07-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Ａｐｅ１媒介疾患を処置するためのキノン化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229004A1 (en) * 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US11331294B2 (en) * 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
CN109602734A (zh) * 2012-03-14 2019-04-12 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
WO2014047782A1 (zh) * 2012-09-25 2014-04-03 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
US20190117602A1 (en) * 2017-04-17 2019-04-25 Indiana University Research And Technology Corporation Prevention and reversal of inflammation induced dna damage
AU2019218797B2 (en) * 2018-02-08 2023-09-21 Indiana University Research And Technology Corporation Targeting ocular diseases with novel APE1/Ref-1 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540544A (ja) * 2007-09-26 2010-12-24 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 癌および血管新生の治療のための、化学療法剤と組み合わせたベンゾキノン誘導体ｅ３３３０
JP2010540545A (ja) * 2007-09-26 2010-12-24 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション キノン誘導体、医薬組成物、およびそれらの使用
JP2014516051A (ja) * 2011-05-26 2014-07-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Ａｐｅ１媒介疾患を処置するためのキノン化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. PHARMACOL. EXP. THER., 2018.10, VOL.367, NO.1, PP.108-118, JPN6021050169, ISSN: 0004667095 *
VISION RESEARCH, 2011, VOL.51, PP.93-100, JPN6021050170, ISSN: 0004823544 *

Also Published As

Publication number Publication date
US20190160034A1 (en) 2019-05-30
EP3430057A4 (en) 2020-03-11
US20230293471A1 (en) 2023-09-21
CA3056240A1 (en) 2018-09-27
EP3735968A1 (en) 2020-11-11
EP3430057A1 (en) 2019-01-23
US11648226B2 (en) 2023-05-16
WO2018175429A1 (en) 2018-09-27
US20210038553A1 (en) 2021-02-11
US12350247B2 (en) 2025-07-08

Similar Documents

Publication Publication Date Title
US12350247B2 (en) Use of APE1/Ref-1 inhibitors for treatment of retinal diseases
Shah et al. Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
US20220226336A1 (en) Combination therapy for treating cancer
US20230107195A1 (en) Treatment of cancer with smg1-inhibitors
Cao et al. Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer
EP3004396B1 (en) Compositions for the treatment of cancer
CN107614062A (zh) 用RORγ抑制剂治疗癌症的方法
Entrialgo-Cadierno et al. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
She et al. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress
WO2017079558A1 (en) TARGETING CASEIN KINASE-1 AND PI3K/AKT/mTOR PATHWAYS FOR TREATMENT OF C-MYC-OVEREXPRESSING CANCERS, ORGAN TRANSPLANT ASSOCIATED COMPLICATIONS AND AUTOIMMUNE DISEASES
Newell et al. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
US20240398804A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
WO2018167519A1 (en) Biomarker for identifying responders to cancer treatment
Soncini et al. Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
US20220288067A1 (en) Treatment of cancer with cdk inhibitors
KR20150131155A (ko) 종양 약역학적 반응의 바이오마커
US20230366033A1 (en) Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair
US20200031920A1 (en) Combination Therapy for Treating Cancer
US20240156800A1 (en) Ep300 degrader and uses thereof in neuroblastoma
Curley et al. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients
US20220296583A1 (en) Compositions and methods for treatment of ovarian and breast cancer
US20250146080A1 (en) Methods for overcoming tazemetostat-resistance in cancer patients
Bashiri Elucidating The Oncogenic Roles of MARCH5 in Multiple Myeloma
Wang Synthetic Essentiality of TNFSF10/TRAIL in VHL-Deficient Renal Cell Carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220712